专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050203011A1 Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity 审中-公开
标题翻译：通过调节GDNF或BDNF通路活性减轻药物滥用的症状和行为
公开(公告)号：US20050203011A1
公开(公告)日：2005-09-15
申请号：US10946625
申请日：2004-09-20
申请人： Dorit Ron
发明人： Dorit Ron
IPC分类号： A61K38/12 , C12Q1/48 , C12Q1/68 , G01N33/53 , G01N33/567
CPC分类号： C12Q1/6883 , A61K38/00 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/5058 , G01N33/566 , G01N33/9413
摘要： This invention pertains to the discovery that brain-derived neurotrophic factor (BDNF) and its associated signaling pathway is involved in reversing and/or counteracting neuroadaptations within the mesolimbic system that contribute to the development and/or maintenance of addiction (e.g. alcohol addiction). This invention also pertains to the discovery that ibogaine activity is mediated by changes in mRNA expression of GDNF. Thus, in certain embodiments, this inventioni provides a method of mitigating one or more symptoms of substance abuse in a mammal by increasing the expression or activity of GDNF, BDNF, RACK1, and/or the dopamine D3 receptor (D3R) in said mammal.
摘要翻译：本发明涉及脑衍生的神经营养因子（BDNF）及其相关的信号传导途径涉及逆转和/或抵消有助于开发和/或维持成瘾（例如酒精成瘾）的中脑边缘系统内的神经适应症。本发明还涉及ibogaine活性由GDNF的mRNA表达变化介导的发现。因此，在某些实施方案中，本发明提供了通过增加所述哺乳动物中GDNF，BDNF，RACK1和/或多巴胺D3受体（D3R）的表达或活性来减轻哺乳动物中一种或多种药物滥用症状的方法。

2. 发明申请

US20090258869A1 METHODS AND COMPOUNDS FOR TREATMENT OR PREVENTION OF SUBSTANCE-RELATED DISORDERS 审中-公开
标题翻译：用于治疗或预防与物质相关的疾病的方法和化合物
公开(公告)号：US20090258869A1
公开(公告)日：2009-10-15
申请号：US12367412
申请日：2009-02-06
申请人： Dorit RON , Dao-Yao He
发明人： Dorit RON , Dao-Yao He
IPC分类号： A61K31/5365 , A61K31/4985 , A61K31/4188
CPC分类号： A61K31/00 , A61K31/395 , A61K31/4188 , A61K31/4985 , A61K31/5383
摘要： The present disclosure provides methods of treating or preventing a substance-related disorder using Hsp90 inhibitors, Hsp90 modulators, tyrosine hydroxylase modulators, and modulators that reduce the interaction between Hsp90 and tyrosine hydroxylase.
摘要翻译：本公开提供使用Hsp90抑制剂，Hsp90调节剂，酪氨酸羟化酶调节剂和减少Hsp90与酪氨酸羟化酶之间的相互作用的调节剂来治疗或预防物质相关疾病的方法。

3. 发明授权

US06423684B1 WD-40 derived peptides and uses thereof 失效
标题翻译： WD-40衍生的肽及其用途
公开(公告)号：US06423684B1
公开(公告)日：2002-07-23
申请号：US08487072
申请日：1995-06-07
申请人： Daria Mochly-Rosen , Dorit Ron
发明人： Daria Mochly-Rosen , Dorit Ron
IPC分类号： A61K3816
CPC分类号： C07K14/00 , C07K5/1024 , C07K14/4722 , C07K14/705
摘要： The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e.g., RACK1).
摘要翻译：本发明涉及有效改变与第二种蛋白质相互作用的第一种蛋白质的活性的多肽组合物，其中第二种蛋白质含有至少一种WD-40区域。本发明的多肽通常具有4至50个氨基酸，其序列与第二蛋白质的WD-40区域中相同长度的序列相同。本发明还包括改变上述第一种蛋白质的活性的方法。在本发明的一个实施方案中，多肽组合物有效地改变蛋白激酶C的活性，其中蛋白激酶C与第二蛋白质相互作用，第二蛋白质含有至少一个WD-40区域（例如RACK1）。

4. 发明授权

US06342368B1 WD-40-derived peptides and uses thereof 失效
标题翻译： WD-40衍生的肽及其用途
公开(公告)号：US06342368B1
公开(公告)日：2002-01-29
申请号：US08473089
申请日：1995-06-07
申请人： Daria Mochly-Rosen , Dorit Ron
发明人： Daria Mochly-Rosen , Dorit Ron
IPC分类号： C12P2106
CPC分类号： C07K5/1024 , C07K14/00 , C07K14/4722 , C07K14/705
摘要： The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e.g., RACK1).
摘要翻译：本发明涉及有效改变与第二种蛋白质相互作用的第一种蛋白质的活性的多肽组合物，其中第二种蛋白质含有至少一种WD-40区域。本发明的多肽通常具有4至50个氨基酸，其序列与第二蛋白质的WD-40区域中相同长度的序列相同。本发明还包括改变上述第一种蛋白质的活性的方法。在本发明的一个实施方案中，多肽组合物有效地改变蛋白激酶C的活性，其中蛋白激酶C与第二蛋白质相互作用，第二蛋白质含有至少一个WD-40区域（例如RACK1）。

5. 发明授权

US6054286A Methods to identify immunomodulators using cognate interaction of PKC-theta 有权
标题翻译：使用PKC-θ的同源相互作用鉴定免疫调节剂的方法
公开(公告)号：US6054286A
公开(公告)日：2000-04-25
申请号：US232130
申请日：1999-01-15
申请人： Hugo O. Villar , John Patterson , Anna Voronova , Dorit Ron , Lawrence Kauvar , Gene Napolitano , Nicki Vasquez
发明人： Hugo O. Villar , John Patterson , Anna Voronova , Dorit Ron , Lawrence Kauvar , Gene Napolitano , Nicki Vasquez
IPC分类号： C12Q1/48
CPC分类号： C12Q1/48 , Y10S435/975
摘要： Compounds having immunomodulating activity are identified using a methodology which employs TER14687, TER10311 and/or TER17210 as standards. The effect candidate compounds have on PKC-theta interaction with cognate binding proteins is measured and compared with the standards. The interaction can be measured by a variety of techniques, including assessing translocation of said PKC-theta or fragment. Kits containing the TER14687, TER10311 and/or TER17210 standards are disclosed. TER14687, TER10311 and/or TER17210 are useful in modulating the immune system in a subject by reducing T-cell activity. TER14687, TER10311, TER17210 are used as leads to develop other compounds having immunomodulating activity.
摘要翻译：使用采用TER14687，TER10311和/或TER17210作为标准的方法鉴定具有免疫调节活性的化合物。测量候选化合物对PKC-theta与同源结合蛋白的相互作用的影响并与标准进行比较。可以通过各种技术测量相互作用，包括评估所述PKC-θ或片段的易位。公开了包含TER14687，TER10311和/或TER17210标准的试剂盒。 TER14687，TER10311和/或TER17210可用于通过降低T细胞活性来调节受试者中的免疫系统。 TER14687，TER10311，TER17210用作开发其他具有免疫调节活性的化合物。

6. 发明授权

US5519003A WD-40-derived peptides and uses thereof 失效
公开(公告)号：US5519003A
公开(公告)日：1996-05-21
申请号：US190802
申请日：1994-02-01
申请人： Daria Mochly-Rosen , Dorit Ron
发明人： Daria Mochly-Rosen , Dorit Ron
IPC分类号： G01N33/566 , C07K5/117 , C07K14/00 , C07K14/47 , C07K14/705 , C12N1/21 , C12N15/09 , C12N15/12 , C12P21/02 , C12R1/19 , G01N33/573 , A61K38/08 , C07K7/06
CPC分类号： C07K5/1024 , C07K14/00 , C07K14/4722 , C07K14/705
摘要： The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e.g., RACK1).

7. 发明授权

US5783405A Rapid screening method for effectors of signal transduction 失效
标题翻译：信号转导效应物的快速筛选方法
公开(公告)号：US5783405A
公开(公告)日：1998-07-21
申请号：US541964
申请日：1995-10-10
申请人： Daria Mochly-Rosen , Dorit Ron , Lawrence M. Kauvar , Eugene W. Napolitano
发明人： Daria Mochly-Rosen , Dorit Ron , Lawrence M. Kauvar , Eugene W. Napolitano
IPC分类号： A61K38/00 , C07K5/117 , C07K14/00 , C07K14/47 , C07K14/705 , C12N9/12 , G01N33/50 , G01N33/566 , C12Q1/48 , C12Q1/68
CPC分类号： C07K5/1024 , C07K14/00 , C07K14/4722 , C07K14/705 , C12N9/1205 , G01N33/505 , G01N33/566 , A61K38/00
摘要： Methods for assessing libraries of candidate modulators of intracellular signaling transmission pathways are described. The methods assess the ability of candidates from the library to inhibit the binding of peptides which represent participants in the signaling pathways as either a signal-generating protein or its cognate partner binding at a noncatalytic site. Specific peptides useful in this regard have been identified.
摘要翻译：描述了评估细胞内信号转导途径的候选调节剂文库的方法。该方法评估了来自文库的候选物抑制代表信号传导途径中参与者的肽与在非催化部位结合的信号产生蛋白或其同源伴侣的结合的能力。已经鉴定了在这方面有用的特异性肽。

8. 发明授权

US5776716A Methods for identifying agents which block the interaction of fyn with PKC-theta, and uses thereof 失效
标题翻译：用于鉴定阻断fyn与PKC-θ的相互作用的试剂的方法及其用途
公开(公告)号：US5776716A
公开(公告)日：1998-07-07
申请号：US594447
申请日：1996-01-31
申请人： Dorit Ron , Eugene W. Napolitano , Anna Voronova
发明人： Dorit Ron , Eugene W. Napolitano , Anna Voronova
IPC分类号： A61K38/00 , C07K5/117 , C07K14/00 , C07K14/47 , C07K14/705 , C12N9/12 , G01N33/50 , G01N33/566 , C12Q1/48 , C12Q1/70
CPC分类号： C07K5/1024 , C07K14/00 , C07K14/4722 , C07K14/705 , C12N9/1205 , G01N33/505 , G01N33/566 , A61K38/00
摘要： The present invention discloses that the fyn protein binds to the PKC-theta protein. Based on this observation, the present invention provides methods of identifying agents which can be used to modulate immune system activity by blocking fyn/PKC-theta binding and therapeutic methods using such agents.
摘要翻译：本发明公开了fyn蛋白结合PKC-θ蛋白。基于该观察，本发明提供了通过使用这种试剂阻断fyn / PKC-θ结合和治疗方法来鉴定可用于调节免疫系统活性的药剂的方法。

9. 发明申请

US20070148660A1 Treatment of maladaptive substance use with H-ras antagonists 审中-公开
标题翻译：用H-ras拮抗剂治疗适应不良物质
公开(公告)号：US20070148660A1
公开(公告)日：2007-06-28
申请号：US11453560
申请日：2006-06-14
申请人： Dorit Ron
发明人： Dorit Ron
IPC分类号： C12Q1/68 , G06F19/00
CPC分类号： C12Q1/6883 , C12Q2600/158
摘要： The present invention provides a method of mitigating a symptom of maladaptive substance use in a subject by inhibiting H-ras. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a symptom of maladaptive substance use. Methods of the invention can involve assaying test agent binding to H-ras. Alternatively, test agents can be screened for their ability to alter the level of H-ras polypeptides, polynucleotides, or function. Finally, the invention also provides a diagnostic method that entails measuring one or more of these levels and determining risk for maladaptive substance use based on comparison to the corresponding level for a control population.
摘要翻译：本发明提供了通过抑制H-ras来减轻受试者中适应不良物质的症状的方法。此外，本发明提供了各种预筛选和筛选方法，其目的在于鉴定调节适应不良物质使用症状的药剂。本发明的方法可以包括测定与H-ras结合的测试剂。或者，可以筛选测试试剂改变H-ras多肽，多核苷酸或功能水平的能力。最后，本发明还提供了一种诊断方法，其需要测量这些水平中的一个或多个并且基于与对照群体的相应水平的比较来确定适应不良物质使用的风险。

10. 发明授权

US06262023B1 WD-40 derived peptides and uses thereof 失效
标题翻译： WD-40衍生的肽及其用途
公开(公告)号：US06262023B1
公开(公告)日：2001-07-17
申请号：US08477346
申请日：1995-06-07
申请人： Daria Mochly-Rosen , Dorit Ron
发明人： Daria Mochly-Rosen , Dorit Ron
IPC分类号： A61K3800
CPC分类号： C07K5/1024 , C07K14/00 , C07K14/4722 , C07K14/705
摘要： The present invention relates to a polypeptide composition effective to alter the activity of a first protein that interacts with a second protein, where the second protein contains at least one WD-40 region. The polypeptides of the present invention typically have between 4 and 50 amino acids whose sequence is the same as a sequence of the same length in the WD-40 region of the second protein. The invention further includes a method of altering the activity of the above described first protein. In one embodiment of the invention the polypeptide composition is effective to alter the activity of a protein kinase C, where the protein kinase C interacts with a second protein, and the second protein contains at least one WD-40 region (e.g., RACK1).
摘要翻译：本发明涉及有效改变与第二种蛋白质相互作用的第一种蛋白质的活性的多肽组合物，其中第二种蛋白质含有至少一种WD-40区域。本发明的多肽通常具有4至50个氨基酸，其序列与第二蛋白质的WD-40区域中相同长度的序列相同。本发明还包括改变上述第一种蛋白质的活性的方法。在本发明的一个实施方案中，多肽组合物有效地改变蛋白激酶C的活性，其中蛋白激酶C与第二蛋白质相互作用，第二蛋白质含有至少一个WD-40区域（例如RACK1）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式